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Background: The vascular endothelial growth factor inhibitor bevacizumab (BEV) given in 
combination with interferon-α-2a (IFN), and the tyrosine kinase inhibitors (TKIs) sunitinib 
(SUN) and pazopanib (PAZ), have all shown significant increase in progression-free survival 
(PFS) in first-line metastatic renal-cell carcinoma (mRCC) therapy. These targeted therapies 
are currently competing to be primary choice; hence, in the absence of direct head-to-head 
comparison, there is a need for valid indirect comparison assessment.
Methods: Standard indirect comparison methods were applied to independent review PFS data 
of the pivotal Phase III trials, to determine indirect treatment comparison hazard-ratios (HR) 
with 95% confidence intervals (95% CI). As BEV+IFN and SUN have been compared to IFN, 
indirect comparison was enabled by the common IFN comparator arms. As PAZ was compared 
to placebo (PLA), a connector trial (IFN vs PLA) was required for the indirect comparison to 
BEV+IFN. Sensitivity analyses taking into account real-life influence of patient compliance on 
clinical outcomes were performed.
Results: The indirect efficacy comparison resulted in a statistically nonsignificant PFS dif-
ference of BEV+IFN vs SUN (HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and of BEV+IFN vs 
PAZ (range based on different connector trials; HR: 0.74–1.03; P = 0.34–0.92). Simulating 
real-life patient compliance and its effectiveness impact showed an increased tendency towards 
BEV+IFN without reaching statistical significance.
Conclusions: There is no statistically significant PFS difference between BEV+IFN and TKIs 
in first-line mRCC. These findings imply that additional treatment decision criteria such as 
tolerability and therapy sequencing need to be considered to guide treatment decisions.
Keywords: indirect treatment comparison, progression-free survival, renal cell carcinoma, 
bevacizumab, sunitinib, pazopanib
Introduction
Metastatic renal-cell carcinoma (mRCC) has always been one of the most drug-resistant 
malignancies1 and the 5-year survival rates remain low at only around 10% and had 
not improved by 2008.2,3
Over the past two decades, immunomodulating drugs such as interferon-α-2a 
(IFN) have been the standard first-line mRCC treatment,4 and have been considered 
the standard comparator in clinical trials.5 Recent advances in understanding the 
molecular biology of kidney cancer have resulted in the development of drugs that 
target known molecular pathways which are believed to be important in this disease, 
such as vascular endothelial growth factors and their receptors.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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The vascular endothelial growth factor inhibitor beva-
cizumab (BEV) given in combination with IFN, and the 
tyrosine kinase inhibitors (TKIs) sunitinib (SUN) and 
pazopanib (PAZ), have all shown significant increase in 
progression-free survival (PFS) in first-line mRCC therapy. 
These targeted therapies are currently competing to be the 
primary choice for the first-line therapy of mRCC patients 
presenting a good or intermediate prognosis. Hence, in the 
absence of direct head-to-head comparison, there is a need 
for valid indirect comparison assessment.
Material and methods
Pivotal trial outcomes
The published Phase III pivotal trial PFS outcomes have been 
selected as the basis of the indirect treatment comparison 
(ITC), as these present the highest quality data based on 
independent central review assessment. Within these pivotal 
trials BEV+IFN6 and SUN7 have each shown a significant 
increase in PFS vs IFN in first-line mRCC therapy, whereas 
PAZ has shown a significant PFS increase compared to 
placebo (PLA),8 as shown in Figure 1.
The PFS hazard ratios (HRs) were selected as the 
preferred outcome for the ITC, as this effect measure 
accounts for censoring and incorporates time to event 
information.9
The independent review PFS HR of BEV+IFN vs IFN 
is 0.57 (95% confidence intervals [95% CI]: 0.45–0.72;   
P , 0.0001),6 the PFS HR of SUN vs IFN is 0.54 (95% CI: 
0.44–0.66; P , 0.00001)7 and the PFS HR of PAZ vs PLA 
is 0.40 (95% CI: 0.27–0.60; P , 0.001),8 respectively.
The BEV+IFN study named AVOREN and the SUN trial 
focused on treatment-naïve mRCC patients   (first-line popu-
lation), whereas the PAZ study included both   treatment-naïve 
and pretreated mRCC patients. Hence for the ITC the 
pazopanib results of treatment-naïve patients have been 
applied, based on prespecified subgroup analysis.
As shown in Table 1 study designs, patient charac-
teristics, enrolment criteria, and study measurements are 
comparable, but not identical, between the AVOREN trial, 
the SUN trial, and the PAZ study.
AVOREN and the PAZ trial were double-blinded 
  placebo-controlled randomized trials, whereas the SUN 
study was a randomized open-label study. Furthermore, 
within the AVOREN trial 100% of patients were neph-
rectomized (inclusion criteria) whereas in the SUN 
and the PAZ trial 88%–91% of patients had a previous 
nephrectomy. Another difference is that the SUN and the 
PAZ trials included more patients with a favorable prog-
nosis (MSKCC risk score 0: 34%–39%) compared to the 
AVOREN study (27%–29%). Although both factors are 
regarded as predictive for the PFS outcome, the between-
study differences are small, hence performing an indirect 
treatment comparison (ITC), without applying adjustments 
for patient characteristics variations, was regarded as an 
appropriate approach.
Indirect treatment comparison approach
The indirect treatment comparison of PFS outcomes of 
BEV+IFN vs SUN and vs PAZ uses the most widely 
applied indirect comparison approach by Bucher et al.12 
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Figure 1 Pivotal Phase III progression-free survival outcomes in first-line mRCC therapy.
Note: PAZ study results refer to the first-line sub-population.
Abbreviations: AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; CI, confidence intervals; IFN, interferon-α-2a; HR, hazard ratio; PAZ, pazopanib; PFS, 
progression-free survival; PLA, placebo; SUN, sunitinib.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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The Canadian Agency for Drugs and Technologies in 
Health13 and others14,15 have recently identified this method 
as the most suitable approach for performing indirect treat-
ment comparisons of randomized controlled trials.
As BEV+IFN and SUN have been compared to IFN, 
indirect comparison was enabled by the common IFN control 
arms, whereas for comparing BEV+IFN vs PAZ a connector 
trial (IFN vs PLA) is required, as shown in Figure 2.
For the identification of suitable connector trials a sys-
tematic literature search was performed using the following 
literature databases: PubMed, Embase, and Cochrane Central 
Register of Controlled Trials. As a result only three IFN 
studies have been identified that provided a suitable PFS 
HR compared to the Phase III trial outcomes (median PFS 
of IFN ≈ 5 months and median PFS for PLA ≈ 3 months) 
in treatment-naïve mRCC patients. Although none of these 
compared IFN vs PLA, the selected studies compared IFN 
regimens either to placebo-like therapy (MRCRCC trial16) or 
to other IFN regimens that had a placebo-like PFS outcome 
(Aass et al17 and Mickisch et al18). In the absence of a valid 
IFN vs PLA connector trial all of these studies have been 
used to perform the ITC of BEV+IFN vs PAZ. Furthermore 
a PFS HR was estimated (‘proxy comparison’) based on 
the median PFS time of IFN (5.4 months6) and of placebo 
(2.8 months8) by assuming constant hazards (HR IFN vs 
PLA = 2.8 m/5.4 m = 0.52). The selected connector trials 
and the PFS HRs applied for IFN vs PLA are shown in 
Table 2.
The indirect comparisons of BEV+IFN vs SUN and 
BEV+IFN vs PAZ were performed for two key scenarios:
1.	 Indirect efficacy comparison: comparison of the Phase III 
results as published.
2.	 Indirect effectiveness assessment based on simulating 
the impact of patient compliance.
Table 1 Comparison of the main study design, patient characteristics, enrolment criteria, and study measurements of the underlying 
pivotal trials
Parameter AVOREN study6,10 SUN study7,11 PAZ study8
BEV+IFN  
(n = 327)
IFN  
(n = 322)
SUN  
(n = 375)
IFN  
(n = 375)
PAZ  
(n = 290)
PLA  
(n = 145)
Study design Double-blinded placebo  
controlled RCT
Open-label RCT Double-blinded placebo 
controlled RCT
Immunotherapy-naïve (%) 100% 100% 100% 100% 53%a 54%a
Nephrectomized (%) 100% 100% 91% 89% 89% 88%
Clear-cell histology (%) 100% 100% 100% 100% 100% 100%
Female (%) 32% 27% 29% 28% 32% 25%
Median age (range) 61 (30–82) 60 (18–81) 62 (27–87) 59 (34–85) 59 (28–85) 60 (25–81)
MSKCC risk score 0 (%) 27% 29% 38% 34% 39% 39%
MSKCC risk score 1–2 (%) 56% 56% 56% 59% 55% 53%
MSKCC risk score $3 (%) 9% 7% 6% 7% 3% 3%
MSKCC risk score NA (%) 9% 7% 0% 5% 3% 4%
Tumor assessment RECIST RECIST RECIST
Note: aPatient characteristics refer to the overall population including therapy-naïve and pretreated patients however the PFS outcomes used in the ITC are based on the 
first-line (treatment-naïve) subpopulation.
Abbreviations: AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; IFN, interferon-α-2a; MSKCC, Memorial Sloan-Kettering Cancer Center; NA, not available; 
PAZ, pazopanib; PFS, progression-free survival; PLA, placebo; RCT, randomized controlled trial; RECIST, Response Evaluation Criteria in Solid Tumors; SUN, sunitinib.
vs
Pivotal phase III RCTs AVOREN trial
IFN BEV+IFN
IFN is used as connector
Indirect treatment
comparison
SUN trial
SUN IFN
SUN BEV+IFN
IFN
Study arms
AVOREN trial
IFN BEV+IFN
IFN vs PLA connector trial required
BEV+IFN vs SUN BEV+IFN vs PAZ
PAZ trial
PAZ PLA
PAZ BEV+IFN
IFN PLA
Figure 2 Indirect treatment comparison: efficacy connections between the pivotal trials.
Abbreviations: AVOREN, AVastin fOr RENal cell cancer; BEV, bevacizumab; IFN, interferon-α-2a; PLA, placebo; PAZ, pazopanib; RCT, randomized controlled trial.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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For both scenarios the indirect comparison HR of 
BEV+IFN vs TKIs with 95% CIs are provided. Figure 3 shows 
the detailed calculation pathway defined by Bucher et al,12 
including the BEV+IFN vs SUN comparison.
For the comparison of BEV+IFN vs PAZ the same meth-
odology was applied, but two ITCs needed to be performed in 
contrast to the SUN comparison. In a first step, the ITC HR 
of PAZ vs IFN was calculated (using the published PAZ PFS 
HR and the connector trials’ PFS HR) and in a second step 
this ITC HR result was compared to the published PFS HR of 
BEV+IFN.
All calculations have been performed in Excel 2003 
(Microsoft, Redmond, WA). The ITC calculations can be 
reperformed using the ITC tool20 available from the Canadian 
Agency for Drugs and Technologies in Health, which ensures 
maximum transparency.
Patient compliance
As the TKIs, SUN and PAZ are oral medications that are 
self-administered by the patient and show a considerable 
adverse event profile7,8, compliance effects are expected in 
real-world settings.
Table 2 Overview of selected connector trials
Author Year Comparison Total N Median PFS in months PFS HR 
(95% CI) IFNa PLAa
MRCRCC trial16 1999 IFN vs MPA 335 4.0 3.0 0.72 (0.56–0.92)
Aass et al17 2005 IFN plus 13-CRA vs IFN 320 5.1 3.4 0.66 (0.52–0.85)
Mickisch et al18 2001 IFN plus nephrectomy vs IFN 84 5.8b 3.4b 0.60 (0.36–0.97)
Proxy comparison 2009 IFN vs PLA NA 5.4 2.8 0.52c (0.32–0.72)
Notes: aEstimated median PFS for IFN and PLA, respectively; bMedian time to progression; cEstimated HR based on Phase III median PFS outcomes6,8 assuming constant 
hazards.
Abbreviations: 13-CRA, 13-cis-retinoic acid; HR, hazard ratio; IFN, interferon-α-2a; MPA, medroxy-progesterone acetate; MRCRCC, Medical Research Council Renal 
Cancer Collaborators; NA, not available; PLA, placebo; PFS, progression-free survival.
Description Formula
Start
Basis data: progression-
free survival (PFS) hazard 
ratio (HR) vs IFN
0.57(0.45–0.72)
BEV+IFN SUN
PFS HR (95% CI) vs 
IFN
0.54(0.44-0.66)
Step 1 Calculation of the log-
hazard ratio (LHR)
LHR = LN(HR)
LHRBEV = LN(0.57)
LHRBEV = −0.562
LHRSUN = LN(0.54)
LHRSUN = -0.616
Step 3
Calculation of the standard 
error (SE) of 
the LHR
SELHR =
LN(UCL)-LN(LCL)
2 x 1.96
SEBEV = 0.120 =
LN(0.45)-LN(0.72)
2 x 1.96
SESUN = 0.103 =
LN(0.44)-LN(0.66)
2 x 1.96
Step 2
Calculation of the indirect 
treatment comparison 
hazard ratio (HRITC)
HRITC =
EXP (LHRBEV-LHRSUN)
HRITC= EXP(−0.562 − −0.616)
HRITC = 1.06
Step 4
Calculation of the SE of 
the HRITC (SEITC) SEITC =√SEBEV
2+ SESUN
2 SEITC=√ 0.1202+ 0.1032
SEITC = 0.158
Step 5
Calculation of the ITC 95% 
Confidence Interval 
(95% CIITC)
95% CIITC =
EXP (LN(HRITC) ±1 ,96 
x SEITC)
95%LCI = EXP(LN(1.06) − 1.96x0.158) = 0.78
95%UCI = EXP(LN(1.06) + 1.96x0.158) = 1.45
Result Indirect treatment comparison hazard ratio (95% confidence 
interval) –c omparing BEV+IFN vs SUN
ITC HR (BEV+IFN vs SUN) = 
1.06 (95% CI: 0.78–1.45)
Figure 3 Indirect comparison methodology according to Bucher et al12 showing the calculations for the comparison of BEV+IFN vs SUN.
Notes: Starting with the published PFS HRs, study-specific log-hazard ratios are calculated (step 1) and transferred into an ITC HR (step 2); The indirect treatment 
comparison 95% confidence intervals are calculated using the 95% CI of the published PFS HR (steps 3–5).
Abbreviations: BEV, bevacizumab; IFN, interferon-α-2a; ITC, indirect treatment comparison; SUN, sunitinib.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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In order to estimate patient compliance under routine 
conditions, data obtained from IMS Health were used as 
the basis for the estimation. These data were obtained 
on the basis of 1869 Dutch mRCC patients treated with 
sunitinib. Physician records have been used in order to 
determine patient compliance at different points in time. 
According to these data the median SUN compliance rate 
at 3, 6, and 9 months of SUN therapy was 74%, 72%, and 
71%, respectively.
As there are currently no published data on PAZ patient 
compliance available, it was assumed that the compliance 
rates are comparable to SUN. We performed analyses using 
the conservative estimates of 90%, 80%, and 70% patient 
compliance for the TKIs, respectively.
In order to simulate the compliance impact on the PFS of 
the TKIs an adjustment of the PFS HR was performed. As 
no clinical trial data are available that show the effectiveness 
impact of noncompliance, it was conservatively assumed that 
the PFS HR of noncompliant patients is ‘1’, which means 
the same efficacy as for IFN, and that the published Phase 
III efficacy refers to the compliant patients.
The detailed steps taken to estimate the real-world 
effectiveness (adjusted TKI PFS HR), depending on patient 
compliance, are shown in Figure 4, using a 70% SUN patient 
compliance as an example. The same approach was applied 
for all scenarios analyzed.
As BEV is infused intravenously, the patient either vis-
its the physician to receive the injection or decides to stop 
therapy by not attending. Even though many patients self-
administer the subcutaneous IFN injections (in combination 
with BEV), which might be a potential compliance issue, 
downdosing of IFN has been shown to improve tolerability 
and maintain efficacy.21 Hence it was assumed that missing 
an IFN injection has a limited impact on the PFS HR of 
BEV+IFN, so no patient compliance impact on BEV+IFN 
therapy was simulated.
Results
The indirect efficacy comparison, shown in Figure 5, resulted 
in a statistically nonsignificant PFS difference of BEV+IFN 
vs SUN (ITC HR: 1.06; 95% CI: 0.78–1.45; P = 0.73) and 
of BEV+IFN vs PAZ (range based on different connector 
trials; ITC HR: 0.74–1.03; P = 0.34–0.92).
For the BEV+IFN vs PAZ comparison the two extreme 
scenarios are based on the selected connector trials, whereby 
using the MRCRCC trial resulted in an ITC HR of 1.03 (95% 
CI: 0.61–1.74; P = 0.92) and using the ‘proxy   comparison’ 
resulted in an ITC HR of 0.74 (95% CI: 0.40–1.37; 
P = 0.34).
Simulating real-life patient compliance and its effective-
ness impact on PFS showed an increased tendency towards 
BEV+IFN without reaching statistical significance, as shown 
in Figure 6.
For the comparison of BEV+IFN vs PAZ simulations 
have been performed for the extreme scenarios, which 
means the connector trials producing the highest ITC HR 
(MRCRCC Trial) and the lowest ITC HR (proxy comparison) 
have been analyzed.
Discussion
Comparing the PFS efficacy and effectiveness of BEV+IFN 
vs the TKIs SUN and PAZ in first-line mRCC therapy failed 
to show a significant tendency in favor of one particular 
targeted therapy approach. Additionally, the influence of 
+
Proportion of patients (example)
PFS HR SUN vs IFN
SUN efficacy estimate
Calculation of weighted PFS HR
Adjusted SUN PFS HR
Compliant to SUN Noncompliant
70% 30%
Same efficacy as IFN Phase III efficacy
0.54 1.00
0.54 x 70% = 0.378 1.00 x 30% = 0.300
0.678
Figure 4 Patient compliance PFS adjustment methodology.
Abbreviations: HR, hazard ratio; IFN, interferon-α-2a; PFS, progression-free survival; SUN, sunitinib.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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patient compliance on the PFS was investigated. This indirect 
effectiveness assessment indicates that the PFS outcomes 
with regard to TKIs might be lower in real-world settings. 
However the observed tendency towards a   better effective-
ness of BEV+IFN failed to reach statistical significance.
The main limitation is that our findings are based on 
  indirect evidence. Such an indirect treatment comparison 
has to be regarded as a complementary assessment to clinical 
trials, because it cannot substitute direct evidence. However, 
in the absence of any head-to-head comparison, the indi-
rect treatment comparison approach should be regarded as 
the most valuable way of estimating treatment effects in a 
  statistically accurate manner.
Another limitation is that there is no matching connec-
tor trial available in order to determine an exact ITC hazard 
ratio for the comparison of BEV+IFN vs PAZ. The lack of 
an adequate connector trial, comparing IFN vs PLA, was 
overcome by using different but the most suitable IFN   studies 
in order to enable a bridge to be built between the PAZ and 
the BEV+IFN PFS outcomes. Furthermore, an additional 
‘proxy comparison’ was performed that is based on assuming 
constant hazards to estimate a HR of IFN vs PLA based on 
the available Phase III evidence. The authors would like to 
point out that the application of constant hazards should be 
performed very carefully but in this special case (no adequate 
connector trial available) it was decided to perform this 
analysis to test the credibility of the bridging trials’ HR on 
the ITC results. As no statistically significant difference 
was observed when comparing the PFS HR of BEV+IFN vs 
PAZ, irrespective of the connector trial used, the lack of an 
adequate bridging trial is regarded as having a limited impact 
on the ITC results.
Another limitation is that data on patient compliance to 
TKIs are currently rare. We used IMS data, which refers to 
the Dutch health care system, to estimate the proportion of 
patients who show a limited compliance to TKI therapy. 
As there are no real world investigations available that 
determine the impact of patient compliance on the PFS, we 
used a conservative assumption. However, further research 
is required in order to evaluate a more accurate link between 
patient compliance and its impact on efficacy.
Another aspect to be considered is the difference in 
patient characteristics between the pivotal trials used. 
According to the patient’s risk profile, the AVOREN study 
included fewer patients with a favorable disease prognosis; 
hence the PFS outcomes might be underestimated in com-
parison to SUN and PAZ. However, as all patients have been 
nephrectomized in the AVOREN trial, which is regarded as 
an indicator for a better disease prognosis, these small dif-
ferences in prognostic patient characteristics are estimated 
to compensate each other.
In the past there was a consensus that SUN and BEV+IFN 
are equally effective in terms of PFS in first-line mRCC 
therapy,22 which is in line with our findings. However, 
recent publications23,24 raised doubts about this comparable 
efficacy. Both papers23,24 focused only on investigator-
assessed PFS values and pooled BEV+IFN PFS outcomes 
from a strictly controlled pivotal Phase III trial10 and an 
HR (95% CI) P-value
Hazard ratio
BEV+IFN preferred TKI preferred
1 0
Proxy comparison 0.74 (0.40 –1 .37)
Aass et al17
Mickisch et al18
0.94 (0.56 –1 .59)
P = 0.65 0.86 (0.44 –1 .69)
MRCRCC16 P = 0.92
BEV+IFN vs SUN
2 1.5 0.5
P = 0.34
P = 0.82
1.03 (0.61 –1 .74)
BEV+IFN vs TKIs
1.06 (0.78 –1 .45)
BEV+IFN vs PAZ by connector trial
P = 0.73
Figure 5 Indirect efficacy comparison results PFS HR of BEV+IFN vs TKIs.
Abbreviations: BEV, bevacizumab; IFN, interferon-α-2a; TKI, tyrosine kinase inhibitor; CI, confidence interval; HR, hazard ratio; SUN, sunitinib.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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investigator-initiated trial.25 As a result of this pooling, the 
efficacy of BEV+IFN was decreased on the basis of a lower 
PFS observed in the investigator-initiated trial25 compared 
to the pivotal trial outcomes.10
In order to ensure comparability, it was expected that 
the authors would apply the same procedure for SUN, 
using the pivotal trial11 and the first-line outcomes from the 
SUN expanded-access-study,26,27 but only the pivotal trial 
  outcomes were used for SUN.
An adequate indirect comparison approach should 
take into account pivotal trials performed under the same 
conditions to be comparable and use the highest quality 
data (independent radiology review of PFS). Hence our 
approach focused on the comparison of the pivotal Phase III 
trials, using the highest data quality, in order to ensure 
  comparability of therapy outcomes.
Our findings have been confirmed by another recently 
published indirect treatment comparison performed from 
the perspective of PAZ. McCann et al28 concluded “that 
pazopanib demonstrates no reduction in efficacy compared 
to other approved angiogenesis inhibitors”, which is in line 
with our findings that say ‘there is no significant difference 
in first-line PFS outcomes between BEV+IFN and the TKIs 
SUN and PAZ’. As a consequence there is a need for other 
HR (95%Cl)
70% patient compliance P = 0.19 0.84 (0.65–1.09)
90% patient compliance
80% patient compliance
0.97 (0.73–1.29)
P = 0.46 0.90 (0.69–1.18)
100% patient compliance 1.06 (0.78–1.45)
BEV+IFN vs TKIs
BEV+IFN vs SUN
Hazard ratio
1 0
BEV+IFN preferred TKI preferred
2
1.5 0.5
70% patient compliance P = 0.29 0.83 (0.58–1.18)
90% patient compliance
80% patient compliance
0.95 (0.60–1.50)
P = 0.55 0.88 (0.59–1.31)
100% patient compliance 1.03 (0.61–1.74)
BEV+IFN vs PAZ (MRCRCC Trial)
70% patient compliance P = 0.08 0.68 (0.44–1.05)
90% patient compliance
80% patient compliance
0.72 (0.42–1.24)
P = 0.15 0.70 (0.43–1.14)
100% patient compliance 0.74 (0.40–1.37)
BEV+IFN vs PAZ (proxy comparison)
P = 0.73
P = 0.85
P = 0.92
P = 0.83
P = 0.34
P = 0.24
P-value
Figure 6 Indirect effectiveness comparison results PFS HR of BEV+IFN vs TKIs.
Abbreviations: BEV, bevacizumab; IFN, interferon-α-2a; HR, hazard ratio; CI, confidence interval; TKI, tyrosine kinase inhibitor; PAZ, pazopanib; MRCRCC, Medical 
Research Council Renal Cancer Collaborators.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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clinical decision criteria that might allow an adequate therapy 
selection in first-line mRCC patients. Possible guidance might 
be offered by aspects of available therapy sequencing options, 
sequential therapy outcomes, and by tolerability issues.29
For example there is evidence that BEV+IFN shows a bet-
ter tolerability profile if indirectly compared to SUN, which 
also impacts the costs of managing side effects.30,31 In addition, 
there are first retrospective analyses indicating that BEV+IFN 
first-line enables effective subsequent TKI therapy,6,32 which 
may lead to improved patient outcomes, taking into account 
the complete sequence of mRCC therapies.33,34
Conclusions
In conclusion, in the light of the currently available evi-
dence, there is no statistically significant PFS difference 
between BEV+IFN and TKIs in first-line mRCC therapy. 
In terms of patient compliance there is an efficacy tendency 
in favor of BEV+IFN, but this fails to reach statistical 
significance.
These findings imply that other treatment decision criteria 
such as tolerability and therapy sequencing opportunities 
need to be considered in order to guide adequate therapy 
decisions.
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